Standardisation of arthritogenic adjuvants for evaluating anti-inflammatory and immunosuppressant drugs

Whitehouse, M. W.; Beck, Frances W.J.

doi:10.1007/bf01965224

Cited by 6 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, however, the data on the latter are restricted to the effects on paw swelling caused by the primary and secondary reactions. Because of the differences in the strains of rat used, formulation of the adjuvant, methods of treatment, manner of collecting data and statistical evaluation, the quantitative information from different laboratories is comparable only to a very limited extent [25].…”

Section: Introductionmentioning

confidence: 99%

Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat

Engelhardt¹,

Homma²,

Schnitzler³

1995

Inflamm Res

View full text Add to dashboard Cite

The effects of meloxicam, piroxicam, diclofenac and tenidap on the swelling of hind paws, radiologically-detectable bone and cartilage destruction of hind paws, increase in spleen weight, increase in erythrocyte sedimentation rate and changes in serum protein composition in male Lewis rats with adjuvant arthritis were studied following once-daily oral administration of these drugs for 21 days. All the drugs dose-dependently inhibited hind paw swelling. For equal activity against hind paw swelling caused by the secondary reaction, the required daily dose of piroxicam was about twice that of meloxicam; those of diclofenac and tenidap were about 3.5 and 60 times higher respectively. The bone and cartilage destruction induced by adjuvant arthritis were inhibited by meloxicam at low daily doses and by piroxicam at doses approximately four times those of meloxicam. Diclofenac and tenidap had only a weak effect on radiologically-detectable lesions when administered at doses sufficient to reduce paw swelling. Meloxicam also had a dose-dependent corrective effect on the systemic changes which occur in adjuvant arthritic rats, e.g. increase in spleen weight, increase in erythrocyte sedimentation rate and changes in serum protein composition. Piroxicam produced similar effects, at 3-4 times higher doses. Diclofenac and tenidap did not show comparable effects when administered at appropriate doses. These findings indicate that the action of meloxicam and piroxicam differs from that of diclofenac and tenidap in adjuvant arthritis in the Lewis rat. At oral doses which significantly reduce edema formation, only meloxicam and piroxicam showed a significant effect on systemic parameters of adjuvant disease in the Lewis rat.

show abstract

Section: Introductionmentioning

confidence: 99%

Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat

Engelhardt¹,

Homma²,

Schnitzler³

1995

Inflamm Res

View full text Add to dashboard Cite

show abstract

“…Elsewhere I have made a plea for standardization of chronic irritants such as Freund's adjuvants for eliciting a chronic polyarthritis in susceptible rat strains [7].…”

Section: First Caveat: Purity and Reproducibility Of The Inflammatorymentioning

confidence: 99%

Chronic inflammation: Cellular events

Whitehouse

1976

Agents and Actions

View full text Add to dashboard Cite

“…WHIrEnOUSE and BECK [1] have suggested that one variable which could be easily controlled in the widely used animal model of arthritis (adjuvant-induced disease of the rat) is the composition of the arthritogenic adjuvant. These investigators reported preliminary data for four commercially available adjuvants -the socalled 'modified Perrigens'~).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of some standard arthritogenic adjuvants (‘modified Perrigens’) in male rats

Swingle¹,

Grant²

1977

Agents and Actions

View full text Add to dashboard Cite

Four commercially available arthritogenic adjuvants ('modified Perrigens') were compared with a Mycobacterium butyricum-mineral oil adjuvant for their ability to induce arthritis in male Holtzman rats. The induced arthritides were also compared with respect to their response to treatment with phenylbutazone and cyclophosphamide. Trivial differences were noted among the various adjuvants in their capability to induce the disease, the severity of the disease, or the response of the disease to therapeutic (phenylbutazone) or prophylactic (cyclophosphamide) administration of drugs. It was concluded that any one of the adjuvants was probably suitable for inducing an arthritis in rats for the testing of drugs and that perhaps other variables in the assay are more important in explaining inter-laboratory variation.

show abstract

Standardisation of arthritogenic adjuvants for evaluating anti-inflammatory and immunosuppressant drugs

Abstract: The assistance of interested readers is sought to eliminate one variable factor in drug evaluation using adjuvant disease in rats.

Cited by 6 publications

References 11 publications

Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat

Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat

Chronic inflammation: Cellular events

Evaluation of some standard arthritogenic adjuvants (‘modified Perrigens’) in male rats

Contact Info

Product

Resources

About